Roger Tung, Concert Pharmaceuticals CEO

Pos­i­tive PhI­II re­sults in hand, Con­cert Phar­ma forges ahead with NDA and com­mer­cial­iza­tion plans for hair loss drug

Con­cert Phar­ma­ceu­ti­cals has been wait­ing to tout Phase III da­ta amidst a sell-off of the bulk of its pipeline to Ter­ran Bio­sciences and sev­er­al oth­er events for the biotech. And on Mon­day, the com­pa­ny rolled out the red car­pet.

Con­cert un­veiled topline re­sults from its sec­ond Phase III clin­i­cal tri­al, dubbed THRIVE-AA2, eval­u­at­ing its oral can­di­date cur­rent­ly called CTP-543 in adult pa­tients with mod­er­ate to se­vere alope­cia area­ta. The can­di­date is an in­hibitor of Janus ki­nas­es JAK1 and JAK2.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.